1. Home
  2. HBIO vs AYTU Comparison

HBIO vs AYTU Comparison

Compare HBIO & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$7.93

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.25

Market Cap

27.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBIO
AYTU
Founded
1901
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
27.4M
IPO Year
2000
2015

Fundamental Metrics

Financial Performance
Metric
HBIO
AYTU
Price
$7.93
$2.25
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$18.00
$9.33
AVG Volume (30 Days)
19.3K
31.5K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,176,000.00
$27,632,080.00
Revenue This Year
$4.77
N/A
Revenue Next Year
$8.55
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$0.38
$1.65
52 Week High
$7.90
$3.07

Technical Indicators

Market Signals
Indicator
HBIO
AYTU
Relative Strength Index (RSI) 78.01 49.18
Support Level $5.91 $2.08
Resistance Level N/A $2.32
Average True Range (ATR) 0.32 0.07
MACD 0.12 -0.01
Stochastic Oscillator 100.00 29.54

Price Performance

Historical Comparison
HBIO
AYTU

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: